The interesting thing about a waiting list is that it looks passive. A line of names. A file of forms. A family told to be patient. But a waiting list is an active machine: every day it converts a child's time into somebody else's administrative problem. Elemy was built around the conviction that this machine could be redesigned.
- Elemy began as Sprout Therapy in 2019 and delivered personalized autism care at home and online.
- Its practical product was coordination: evaluation, insurance, matching, scheduling, treatment plans, supervision, and progress data.
- The company raised a reported $270 million and reached a $1.15 billion valuation in 2021.
- Rapid national expansion met labor, reimbursement, and local-service constraints; four rounds of layoffs followed in 2022.
- Elemy retreated from direct care toward provider software. The later chapter appeared under the Tilly Therapy name.
Yury Yakubchyk, an entrepreneur whose parents were physicians, had lived a version of the problem. Diagnosed with ADHD as a child, he watched his family navigate behavioral-health systems across three countries. The problem did not appear to be a shortage of theories. It was the exhausting distance between diagnosis and useful care.
So the company, launched as Sprout Therapy, did something both obvious and ambitious. It put therapists into homes, connected supervising clinicians by telehealth, handled the insurer, and gave families a way to follow progress. For children with autism, the core treatment was applied behavior analysis, or ABA: individualized work on communication, daily skills, social interaction, and behavior, typically reinforced through repetition and play.
The product was the handoff
Calling Elemy a telehealth company misses the point. Much of its therapy happened in person. Calling it an ABA provider also misses the point. Its pitch was that every awkward handoff around therapy could become a designed experience.
A pediatrician could refer a child. A care team would contact the family, work with insurance, arrange an assessment, create a plan, and match the child with clinicians. An in-home Registered Behavior Technician could work with the child while a Board Certified Behavior Analyst supervised the plan. Parents and referring doctors could receive progress updates. Later offerings stretched into speech-language pathology, psychiatric evaluation, anxiety and depression care, and RBT training through eCademy.
The appeal was not mysterious. A parent does not wake up wanting a behavioral-health platform. A parent wants an answer, a person who shows up, a schedule that survives school and work, and some credible sign that the child is progressing. Elemy's advantage over a traditional local clinic was supposed to be speed plus visibility. Company materials said it could match families with care up to four times faster than other providers. Its clinical marketing reported an 85.2 percent reduction in problem behavior after six or more months of therapy. Those were Elemy's own figures, but they expressed the company's thesis neatly: access and measurement belonged in the same product.
Digital health loves the word platform. A family still needs to know who is arriving at the house on Tuesday.
A billion-dollar speed mismatch
Capital arrived faster than care could be standardized. A $10 million seed round in 2020 was followed by a roughly $41 million Series A. In October 2021, SoftBank Vision Fund 2 led a $219 million Series B, with Goodwater Capital and Premji Invest co-leading and a long roster of investors joining. The reported valuation was $1.15 billion.
By then, the company had rebranded as Elemy and grown from a small team to more than 1,000 people in roughly 18 months. It operated a national ambition through local labor markets. That is the detail that matters. Software can be copied into California, Colorado, or Florida with a deploy button. A licensed clinician cannot. Each market brings payer contracts, credentialing, supervision, travel time, canceled sessions, and a different supply of qualified people.
What failed first: the operating model absorbed four rounds of layoffs during 2022. By December, the company described itself as moving toward a near-pure software platform.
The first visible break came through repeated reorganizations. In July 2022, services were restricted to California, Texas, and Florida as other markets were cut. By December, Behavioral Health Business reported a fourth round of layoffs. Yakubchyk said the change moved Elemy closer to an original objective: software that empowered independent clinicians and families without keeping the clinicians on Elemy's payroll.
That explanation is revealing because it is both a pivot and a return. Elemy had raised money on the power of a tightly integrated care model. It then concluded that the most scalable part of the model was the infrastructure: patient matching, automated care-plan development, clinical decision support, outcomes analytics, onboarding, scheduling, and billing workflows. The care provider was becoming the toolmaker.
Own the care journey
Sprout combines family intake, insurance help, in-home therapy, telehealth supervision, and progress tracking.
Scale the integrated model
Elemy adds capital, markets, clinicians, and adjacent pediatric behavioral-health services.
Sell the operating system
Layoffs and market exits precede a shift toward software for independent practices, later associated with Tilly Therapy.
What changed their mind
There is no single public memo that says, here is the day the spreadsheet won. The evidence is operational. Elemy narrowed its footprint, reduced directly employed care teams, and emphasized a treatment-agnostic platform. The economics of a national clinical workforce had begun dictating the product strategy.
This is what makes the story more useful than a simple rise-and-fall tale. The software was not fake. Matching matters. Care plans consume skilled time. Outcome data can improve decisions. Insurance administration can delay treatment before it begins. But the technology worked inside a service, and the service had to be staffed every morning. When venture-funded growth collided with reimbursement and clinician supply, the headcount was not overhead surrounding the product. It was the product arriving at the door.
By 2024, industry reporting described Tilly Therapy as the third brand in a sequence that began with Sprout and passed through Elemy. Tilly marketed practice-management and electronic-health-record software alongside special-education services. The name changed, but the strategic answer was legible: enable smaller providers instead of trying to employ an entire national care network.
The part worth copying
- Design from referral to first session. The worst customer experience often happens before the clinical product begins.
- Treat insurance as a feature. Eligibility checks, authorizations, and plain-language cost expectations create real access.
- Match people, not just time slots. Fit, geography, language, and schedule affect whether care continues.
- Give families a progress loop. A useful dashboard answers what changed, what happens next, and what parents can reinforce.
- Count coordination minutes. If each new patient adds invisible human work, growth may magnify the bottleneck.
The conditions hidden in the model
Elemy's original approach works best where insurers cover the treatment, clinician supply is deep enough for reliable matching, travel distances are manageable, and remote supervision is clinically and legally appropriate. It also depends on families having stable schedules, suitable home environments, and enough trust to invite care inside.
It works poorly where reimbursement lags labor costs, qualified therapists are scarce, cancellations destroy utilization, or a child needs facility-based, multidisciplinary, or high-acuity support. Software can reduce the friction in those conditions. It does not repeal them.
The charming part of Elemy's Pentagram-designed identity was a mark called “The Hug”: two imperfect shapes overlapping to represent child, family, and clinician. It was warm, slightly messy, and more honest than the usual healthtech geometry. The overlap was the business. Elemy's costly discovery was that you cannot keep the symbol and outsource the mess.